Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Cash & Equivalents: 2015-2020

Historic Cash & Equivalents for Outlook Therapeutics (OTLK) over the last 5 years, with Jun 2020 value amounting to $24.0 million.

  • Outlook Therapeutics' Cash & Equivalents rose 70.77% to $24.0 million in Q2 2020 from the same period last year, while for Jun 2020 it was $24.0 million, marking a year-over-year increase of 70.77%. This contributed to the annual value of $8.0 million for FY2019, which is 366.73% up from last year.
  • As of Q2 2020, Outlook Therapeutics' Cash & Equivalents stood at $24.0 million, which was up 414.80% from $4.7 million recorded in Q1 2020.
  • Outlook Therapeutics' Cash & Equivalents' 5-year high stood at $24.0 million during Q2 2020, with a 5-year trough of $81,049 in Q1 2017.
  • For the 3-year period, Outlook Therapeutics' Cash & Equivalents averaged around $7.2 million, with its median value being $5.3 million (2018).
  • As far as peak fluctuations go, Outlook Therapeutics' Cash & Equivalents crashed by 98.97% in 2017, and later spiked by 8,332.33% in 2018.
  • Over the past 5 years, Outlook Therapeutics' Cash & Equivalents (Quarterly) stood at $2.1 million in 2016, then surged by 565.75% to $13.8 million in 2017, then plummeted by 98.35% to $227,716 in 2018, then spiked by 485.62% to $1.3 million in 2019, then spiked by 70.77% to $24.0 million in 2020.
  • Its last three reported values are $24.0 million in Q2 2020, $4.7 million for Q1 2020, and $1.3 million during Q4 2019.